HUE047221T2 - A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal - Google Patents
A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkalInfo
- Publication number
- HUE047221T2 HUE047221T2 HUE13865442A HUE13865442A HUE047221T2 HU E047221 T2 HUE047221 T2 HU E047221T2 HU E13865442 A HUE13865442 A HU E13865442A HU E13865442 A HUE13865442 A HU E13865442A HU E047221 T2 HUE047221 T2 HU E047221T2
- Authority
- HU
- Hungary
- Prior art keywords
- fusions
- treatment
- disease cells
- sirp alpha
- sirp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738008P | 2012-12-17 | 2012-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE047221T2 true HUE047221T2 (hu) | 2020-04-28 |
Family
ID=50977456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19185175A HUE058790T2 (hu) | 2012-12-17 | 2013-12-17 | CD47+ beteg sejtek kezelése SIRP-alfa-Fc fúziókkal |
| HUE13865442A HUE047221T2 (hu) | 2012-12-17 | 2013-12-17 | A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19185175A HUE058790T2 (hu) | 2012-12-17 | 2013-12-17 | CD47+ beteg sejtek kezelése SIRP-alfa-Fc fúziókkal |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9969789B2 (hu) |
| EP (3) | EP4116331A1 (hu) |
| JP (3) | JP6335189B2 (hu) |
| CN (2) | CN105073780B (hu) |
| AU (4) | AU2013362789B8 (hu) |
| CA (2) | CA3145468A1 (hu) |
| CY (1) | CY1122463T1 (hu) |
| DK (2) | DK2931752T3 (hu) |
| ES (2) | ES2914814T3 (hu) |
| HK (1) | HK1217716A1 (hu) |
| HR (1) | HRP20192013T1 (hu) |
| HU (2) | HUE058790T2 (hu) |
| LT (1) | LT2931752T (hu) |
| ME (1) | ME03550B (hu) |
| PL (2) | PL2931752T3 (hu) |
| PT (2) | PT3575326T (hu) |
| RS (1) | RS59591B1 (hu) |
| SI (2) | SI2931752T1 (hu) |
| WO (1) | WO2014094122A1 (hu) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2995315T3 (pl) | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| PT3575326T (pt) * | 2012-12-17 | 2022-05-30 | Pf Argentum Ip Holdings Llc | Tratamento de células de doença cd47+ com fusões sirp alfa-fc |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| HUE050406T2 (hu) | 2014-08-08 | 2020-12-28 | Univ Leland Stanford Junior | Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek |
| CN106535914B (zh) * | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| CA2956126A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| SG10202002131PA (en) | 2015-05-21 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| BR102016018074A2 (pt) * | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| RS62151B1 (sr) | 2015-08-07 | 2021-08-31 | Alx Oncology Inc | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu |
| JP6981973B2 (ja) | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| KR102472087B1 (ko) | 2016-01-11 | 2022-11-29 | 포티 세븐, 인코포레이티드 | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 |
| CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
| EP3442593A4 (en) * | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| CN109803642B (zh) * | 2016-07-15 | 2022-10-14 | 韩国科学技术研究院 | 新型纳米笼及其用途 |
| JP7241677B2 (ja) * | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042581A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
| KR102129067B1 (ko) * | 2016-12-29 | 2020-07-08 | 한국과학기술연구원 | 신규 엑소좀 계열 항암제 |
| CN108277234A (zh) * | 2017-01-05 | 2018-07-13 | 上海白泽生物科技有限公司 | 封闭cd47并激发抗肿瘤免疫的重组溶瘤腺病毒及其用途 |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| CN110546160A (zh) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | 靶向嵌合蛋白及其用途 |
| CN118184797A (zh) | 2017-02-27 | 2024-06-14 | 沙塔克实验室有限公司 | 基于vsig8的嵌合蛋白 |
| CN110381974A (zh) | 2017-02-27 | 2019-10-25 | 沙塔克实验室有限公司 | 基于csf1r的嵌合蛋白 |
| CN110381983B (zh) | 2017-02-27 | 2024-07-09 | 沙塔克实验室有限公司 | 基于tigit和light的嵌合蛋白 |
| EP3600424A4 (en) * | 2017-03-28 | 2020-12-23 | Trillium Therapeutics Inc. | CD47 BLOCKED THERAPY |
| AU2018264321A1 (en) * | 2017-05-08 | 2019-12-12 | Shanghai Jmt-Bio Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
| WO2018209298A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| KR20190037164A (ko) * | 2017-09-28 | 2019-04-05 | 한국과학기술연구원 | 신규 암 치료용 조성물 |
| AU2018346955B2 (en) | 2017-10-13 | 2024-08-29 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
| CA3080640C (en) * | 2017-11-06 | 2024-04-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
| EP3715377A4 (en) * | 2017-11-20 | 2021-06-02 | Taizhou Mabtech Pharmaceutical Co., Ltd | BIFUNCTIONAL FUSION PROTEIN TARGETING CD47 AND PD-L1 |
| PL3752190T3 (pl) | 2018-02-12 | 2022-11-07 | Forty Seven, Inc. | „schemat przeciwnowotworowy z wykorzystaniem przeciwciał anty-cd47 i anty-cd20 |
| CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
| EP3765080A4 (en) * | 2018-03-13 | 2022-03-16 | Trillium Therapeutics Inc. | IMPROVEMENTS IN THERAPY FOR CD47 BLOCKADE BY EGFR ANTIBODIES |
| CN111836647A (zh) * | 2018-03-13 | 2020-10-27 | 延龄草治疗公司 | Cd47阻断疗法和cd38抗体的组合 |
| JP7393342B2 (ja) | 2018-03-21 | 2023-12-06 | エーエルエックス オンコロジー インコーポレイテッド | シグナル調節タンパク質αに対する抗体及び使用方法 |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN110386984B (zh) * | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
| CN108794641A (zh) * | 2018-07-04 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种针对EGFRvIII的多功能融合蛋白及其应用 |
| MX2020013068A (es) | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES |
| US20210309744A1 (en) * | 2018-08-29 | 2021-10-07 | Shattuck Labs, Inc. | Combination therapies comprising pd-1-based chimeric proteins |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| JP2021534769A (ja) * | 2018-08-31 | 2021-12-16 | エーエルエックス オンコロジー インコーポレイテッド | デコイポリペプチド |
| AU2019336345A1 (en) * | 2018-09-04 | 2021-04-15 | Pfizer Inc. | CD47 blockade with parp inhibition for disease treatment |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| US20210393692A1 (en) * | 2018-11-13 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
| WO2020177733A1 (zh) | 2019-03-06 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| AU2020374947A1 (en) | 2019-10-31 | 2022-03-31 | Forty Seven, Inc. | Anti-CD47 and anti-CD20 based treatment of blood cancer |
| KR20220107223A (ko) | 2019-11-27 | 2022-08-02 | 알렉소 온콜로지 인크. | 암 치료를 위한 병용 요법 |
| CN111253482B (zh) * | 2020-02-18 | 2021-11-30 | 中国人民解放军军事科学院军事医学研究院 | SIRPa变体、融合蛋白、及其应用 |
| US20220401516A1 (en) | 2020-06-01 | 2022-12-22 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| CN114057888A (zh) * | 2020-07-30 | 2022-02-18 | 三生国健药业（上海）股份有限公司 | 一种SIRPα-Fc融合蛋白 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP2023546679A (ja) * | 2020-10-22 | 2023-11-07 | アクティニウム ファーマシューティカルズ インコーポレイテッド | がん治療における放射免疫療法とｃｄ４７遮断の併用 |
| EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022229818A1 (en) | 2021-04-27 | 2022-11-03 | Pf Argentum Ip Holdings Llc | Enhancement of cd47 blockade therapy with dhfr inhibitors |
| BR112023022774A2 (pt) | 2021-05-13 | 2024-01-02 | Alx Oncology Inc | Terapias de combinação para tratamento de câncer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| WO2023006390A1 (en) * | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Mesothelin antibodies and use thereof |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
| US20240043846A1 (en) | 2021-11-19 | 2024-02-08 | Kist (Korea Institute Of Science And Technology) | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| AU2022421675A1 (en) * | 2021-12-21 | 2024-05-02 | Fbd Biologics Limited | ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| AU2023240361A1 (en) * | 2022-03-24 | 2024-10-03 | Bitterroot Bio, Inc. | Sirp-alpha fusion polypeptides with modified fc domains |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023183890A1 (en) * | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
| WO2023228044A1 (en) * | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Dosing regimens of sirp alpha fusion proteins for treatment of cancer |
| WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| WO2024025264A1 (en) * | 2022-07-24 | 2024-02-01 | Shiftbio Co., Ltd. | Method for treating cancer and inflammatory diseases using stem cell- derived extracellular vesicles comprising sirp |
| WO2024040151A1 (en) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Sirp alpha fusion protein and anti-cd38 antibody combination therapies |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0914452A2 (en) | 1996-06-17 | 1999-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods |
| US7074589B1 (en) * | 1996-06-17 | 2006-07-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acids encoding BDP-1 |
| US6541615B1 (en) | 1996-11-15 | 2003-04-01 | Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. | SIRP proteins and uses thereof |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| AU1701001A (en) | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| WO2002092784A2 (en) | 2001-05-15 | 2002-11-21 | Emory University | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| US6541516B1 (en) | 2001-09-14 | 2003-04-01 | Isp Investments Inc. | Water miscible emulsions of pyrethroid insecticides or triazole fungicides |
| EP1369128A1 (en) | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| EP2364996B1 (en) * | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| EP1693385A4 (en) | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | ANTI-CD47 ANTIBODIES HUMANIZED |
| JP2008528633A (ja) * | 2005-02-01 | 2008-07-31 | リサーチ ディベロップメント ファウンデーション | Ｂｌｙｓレセプターを標的化するためのｂｌｙｓ融合タンパク質およびｂ細胞増殖性疾患の処置方法 |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| AU2007213709A1 (en) | 2006-02-08 | 2007-08-16 | Targeted Molecular Diagnostics, Llc | Bivalent ErbB ligand binding molecules and methods for their preparation and use |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| AU2007249709A1 (en) | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| JP5189082B2 (ja) * | 2006-05-25 | 2013-04-24 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
| CA2702217A1 (en) | 2007-10-11 | 2009-04-16 | Jayne Danska | Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| US8541543B2 (en) * | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
| DE102007056623B3 (de) | 2007-11-23 | 2009-05-20 | Mtu Friedrichshafen Gmbh | Verfahren zur Regelung eines stationären Gasmotors |
| PT3056514T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação de fagocitose mediada por cd47 |
| WO2009091547A1 (en) | 2008-01-15 | 2009-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP2012512640A (ja) | 2008-12-19 | 2012-06-07 | ノバルティス アーゲー | 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド |
| WO2010083253A2 (en) | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| PL2995315T3 (pl) * | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| JP2013514795A (ja) | 2009-12-22 | 2013-05-02 | ノバルティス アーゲー | 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質 |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| CN103429261A (zh) | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| RS60606B1 (sr) * | 2012-01-17 | 2020-08-31 | Univ Leland Stanford Junior | Reagensi sirp-alfa visokog affiniteta |
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| ES2786083T3 (es) | 2012-12-12 | 2020-10-08 | Arch Oncology Inc | Anticuerpos terapéuticos CD47 |
| PT3575326T (pt) | 2012-12-17 | 2022-05-30 | Pf Argentum Ip Holdings Llc | Tratamento de células de doença cd47+ com fusões sirp alfa-fc |
| BR112015018851A2 (pt) | 2013-02-06 | 2017-07-18 | Inhibrx Llc | anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos |
| EP3188758B1 (en) | 2014-08-08 | 2023-10-04 | The Board of Trustees of the Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| CN106535914B (zh) | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| CA2956126A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| EP3442593A4 (en) | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
| EP3600424A4 (en) | 2017-03-28 | 2020-12-23 | Trillium Therapeutics Inc. | CD47 BLOCKED THERAPY |
-
2013
- 2013-12-17 PT PT191851757T patent/PT3575326T/pt unknown
- 2013-12-17 EP EP22162692.2A patent/EP4116331A1/en active Pending
- 2013-12-17 ME MEP-2019-310A patent/ME03550B/me unknown
- 2013-12-17 RS RS20191446A patent/RS59591B1/sr unknown
- 2013-12-17 DK DK13865442T patent/DK2931752T3/da active
- 2013-12-17 CA CA3145468A patent/CA3145468A1/en active Pending
- 2013-12-17 SI SI201331610T patent/SI2931752T1/sl unknown
- 2013-12-17 HU HUE19185175A patent/HUE058790T2/hu unknown
- 2013-12-17 EP EP13865442.1A patent/EP2931752B1/en active Active
- 2013-12-17 ES ES19185175T patent/ES2914814T3/es active Active
- 2013-12-17 PL PL13865442T patent/PL2931752T3/pl unknown
- 2013-12-17 EP EP19185175.7A patent/EP3575326B8/en active Active
- 2013-12-17 DK DK19185175.7T patent/DK3575326T3/da active
- 2013-12-17 HU HUE13865442A patent/HUE047221T2/hu unknown
- 2013-12-17 SI SI201331996T patent/SI3575326T1/sl unknown
- 2013-12-17 LT LT13865442T patent/LT2931752T/lt unknown
- 2013-12-17 PT PT138654421T patent/PT2931752T/pt unknown
- 2013-12-17 WO PCT/CA2013/001046 patent/WO2014094122A1/en active Application Filing
- 2013-12-17 CN CN201380073010.1A patent/CN105073780B/zh active Active
- 2013-12-17 PL PL19185175T patent/PL3575326T3/pl unknown
- 2013-12-17 AU AU2013362789A patent/AU2013362789B8/en active Active
- 2013-12-17 US US14/653,165 patent/US9969789B2/en active Active
- 2013-12-17 CN CN201910261473.XA patent/CN110066341B/zh active Active
- 2013-12-17 ES ES13865442T patent/ES2755156T3/es active Active
- 2013-12-17 CA CA2894245A patent/CA2894245C/en active Active
- 2013-12-17 JP JP2015548121A patent/JP6335189B2/ja active Active
-
2016
- 2016-05-18 HK HK16105678.0A patent/HK1217716A1/zh unknown
-
2018
- 2018-02-13 AU AU2018201039A patent/AU2018201039A1/en not_active Abandoned
- 2018-04-25 US US15/962,540 patent/US10906954B2/en active Active
- 2018-04-26 JP JP2018084885A patent/JP6664430B2/ja active Active
-
2019
- 2019-11-07 HR HRP20192013TT patent/HRP20192013T1/hr unknown
- 2019-11-13 CY CY20191101192T patent/CY1122463T1/el unknown
-
2020
- 2020-02-17 JP JP2020023936A patent/JP7149450B2/ja active Active
- 2020-03-25 AU AU2020202119A patent/AU2020202119B2/en active Active
- 2020-12-23 US US17/133,489 patent/US20210206829A1/en not_active Abandoned
-
2022
- 2022-11-25 AU AU2022275518A patent/AU2022275518A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217716A1 (zh) | α- 融合蛋白處理 +疾病細胞 | |
| IL288256A (en) | Digital to biological converter | |
| HK1216647A1 (zh) | 治療性 抗體 | |
| HK1205759A1 (en) | Treatment of biomass | |
| BR112015013188A2 (pt) | método de fermentação otimizado | |
| EP2906270A4 (en) | SYRINGE WITH SEVERAL COMPARTMENTS | |
| PT2895071T (pt) | Biosensor implantável dado em forma de cabeça | |
| ZA201205425B (en) | Treatment with vb-201 | |
| GB201506603D0 (en) | Photobioreactor | |
| EP2937327A4 (en) | HFO-1234ZE AND HFC-245FA COPRODUCTION MANUFACTURING METHOD | |
| GB201309274D0 (en) | Treatment Of Fuel | |
| PT2809343T (pt) | Processo de fermentação | |
| ZA201405761B (en) | Pentose fermenting microoranisms | |
| EP2799403A4 (en) | TUBULAR DIGESTER | |
| GB201204645D0 (en) | Treatment of disease | |
| PL398028A1 (pl) | Fotobioreaktor | |
| GB201219431D0 (en) | Helix lift | |
| GB201211286D0 (en) | Novel biological factor | |
| GB201215621D0 (en) | Medical solution |